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Summary
Many cancers possess elevated levels of PtdIns
(3,4,5)P3, the second messenger that induces activa-
tion of the protein kinases PKB/Akt and S6K and
thereby stimulates cell proliferation, growth, and sur-
vival [1, 2]. The importance of this pathway in tumori-
genesis has been highlighted by the finding that
PTEN, the lipid phosphatase that breaks down
PtdIns(3,4,5)P3 to PtdIns(4,5)P2, is frequently mutated
in human cancer [3, 4].Cells lacking PTEN possess
elevated levels of PtdIns(3,4,5)P3, PKB, and S6K activ-
ity [5–8] and heterozygous PTEN+/− mice develop a
variety of tumors [9–11]. Knockout of PKB in PTEN-
deficient cells reduces aggressive growth and pro-
motes apoptosis [12], whereas treatment of PTEN+/−
mice with rapamycin, an inhibitor of the activation of
S6K, reduces neoplasia [13]. We explored the impor-
tance of PDK1, the protein kinase that activates PKB
and S6K [14], in mediating tumorigenesis caused by
the deletion of PTEN. We demonstrate that reducing
the expression of PDK1 in PTEN+/− mice, markedly
protects these animals from developing a wide range
of tumors. Our findings provide genetic evidence that
PDK1 is a key effector in mediating neoplasia result-
ing from loss of PTEN and also validate PDK1 as a*Correspondence: j.bayascas@dundee.ac.uk (J.R.B.); s.fleming@
dundee.ac.uk (S.F.)promising anticancer target for the prevention of tu-
mors that possess elevated PKB and S6K activity.
Results and Discussion
Generation of PDK1 Hypomorphic PTEN+/− Mice
In this study we explore whether suppression of PDK1
expression inhibits tumorigenesis in PTEN+/− mice. As
PDK1−/− mice fail to develop beyond embryonic day
(E)9.5 of embryogenesis, we generated hypomorphic
PDK1fl/fl mice in which the neomycin resistance gene is
inserted into an intron sequence between exons 2 and
3 of the PDK1 gene in order to interfere with its expres-
sion (Figure 1A) [15]. The presence of the neomycin
gene reduces the expression of PDK1 by 80%–90% in
all tissues, and its removal using the CRE recombinase
restores normal levels of PDK1 [15]. PDK1fl/fl mice, as
well as PDK1−/fl mice possessing even lower levels of
PDK1, are viable and fertile, and the only marked phe-
notype is that they are 30%–40% smaller than control
littermates [15].
We crossed the hypomorphic PDK1−/fl mice with
PTEN+/− mice as described in Figure 1B in order to
generate a group of experimental PDK1−/flPTEN+/− and
littermate control PDK1+/flPTEN+/−mice. PDK1 hypo-
morphic mice, which are wild-type for PTEN (PDK1−/fl
PTEN+/+), are born at a reduced Mendelian frequency
(Figure 1B, cross 3 and [15]), indicating that reduced
PDK1 expression affects the development of some
mice. Interestingly however, the PDK1−/flPTEN+/− mice
are born at the expected frequency. There is evidence
that PTEN+/− cells possess enhanced activity of the PI
3-kinase pathway [16, 17], which might be capable of
rescuing the loss of viability resulting from a reduction
in PDK1 expression. It is not possible to generate
PTEN−/− mice as they die early in embryogenesis [9–
11], and we have also been unable to generate viable
PTEN−/−PDK1−/fl mice (Figure 1B, cross 4), indicating
that a reduction in PDK1 cannot rescue embryonic le-
thality resulting from complete loss of PTEN.
The group of experimental PDK1−/flPTEN+/− mice are
w30% smaller than their littermate control PDK1+/fl
PTEN+/− mice at 6 weeks of age and remain smaller
until 12 months of age (Figure 1C). Thus any increase
in PtdIns(3,4,5)P3 in the PTEN+/− mice does not com-
pensate for the effect on cell size resulting from the
hypomorphic mutation of PDK1. We measured PDK1
activity and its expression in the liver (Figure 1D), as
well as muscle and adipose tissue (data not shown) and
found that, as expected, PDK1 activity and protein
levels in the experimental PDK1−/flPTEN+/− animals are
markedly reduced. We also found that PTEN activity
and expression of the protein is the same in the liver
(Figure 1E) and muscle and adipose tissues obtained
from both the experimental PDK1−/flPTEN+/− and the
control PDK1+/flPTEN+/− animals (data now shown).
Analysis of Survival
Up to 9 months of age there is no significant difference
in the overall survival of the experimental PDK1−/fl
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1840Figure 1. Generation and Analysis of PDK1 Hypomorphic PTEN+/− Mice
(A) Diagram illustrating the positions of the exons 2 to 5 of the PDK1 gene [15] and 4 to 6 of the PTEN gene [11], depicting the different alleles
that we have utilized. The black boxes represent exons, the continuous lines introns, and triangles represent CRE loxP excision site and NEO
the neomycin resistance gene cassette.
(B) Breeding strategy employed to generate the control PDK1+/flPTEN+/− and experimental PDK1−/flPTEN+/− mice used in this study. The
number and percentage of each genotype obtained after weaning are indicated. An asterisk indicates lower frequency than expected of
PDK1−/flPTEN+/+ obtained is statistically significant (χ2 Test and Fisher’s Exact Test p < 0.05).
(C) The mean body weight of the control PDK1+/flPTEN+/− and experimental PDK1−/flPTEN+/− mice at the indicated age, where n corresponds
to the number of mice in each group. Values represent the mean ± SEM for each data point.
(D and E) Liver extracts for the indicated mice were prepared and PDK1 (D) or PTEN (E) were immunoprecipitated and assayed. The results
shown are the average ± SEM corresponding to samples derived from three independent mice assayed in triplicate. Samples from three
different mice of each genotype were also immunoblotted with the indicated antibodies. The double asterisks in (C) and (D) indicates p <
0.005 as obtained by the Student’s t test.PTEN+/− and control PDK1+/flPTEN+/− mice. We observed
that w20% of both groups of animals died spontane-
ously (Figure 2A). Pathological analysis of the mice
that died during this period revealed that only a single
7-month-old PDK1+/flPTEN+/− control mouse had lym-
phoma, whereas the other animals possessed no de-
tectable tumors or preneoplastic lesions (data not
shown). It has been reported previously that PTEN+/−
mice have a tendency to develop lethal polyclonal auto-
immune disorder, resulting in renal failure [17]. We ob-
served that several of the PDK1−/flPTEN+/− or PDK1+/fl
PTEN+/− mice that died within the first 9 months dis-
played kidney disease, predominantly glomerulonephri-
tis, similar to that previously reported [17] (data not
shown).
After 9 months of age, a significant number of control
PDK1+/flPTEN+/− mice developed large, externally visi-
ble tumors, and by 12 months of age 40% of these mice
displayed such tumors (Figure 2B). In striking contrast,
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pone of the experimental PDK1−/flPTEN+/− mice dis-
layed externally visible tumors up to 14–15 months of
ge when the study was terminated. At this stage, only
out of 23 experimental animals were observed to pos-
ess obvious tumors, which were only visible following
issection (Figure 2B). In contrast, 68% of the control
DK1+/flPTEN+/− mice possessed at least 1 obvious tu-
or by 14–15 months of age.
nalysis of Tumors
ice were culled when they exhibited large external tu-
ors, lost weight, became sick or reached 15 months
f age. A necroscopy was performed, the tissues fixed
n 10% formalin, and subjected to detailed histopatho-
ogical examination. The types of tumors and the pro-
ortion of mice displaying these lesions are summa-
ized in Table 1 and representative histopathological
ections are shown in Figure 3. Similar to previous re-
orts for the PTEN+/− mice [9–11], we observed that
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1841Figure 2. Analysis of Survival and Tumor For-
mation
(A) Mice were maintained under standard
husbandry conditions and the percentage of
surviving mice is indicated.
(B) The percentage of mice with visible tu-
mors is indicated. For mice up to 12 months
of age, these tumors only comprise those
that were externally visible. At 14–15 months
of age when the study was terminated, tu-
mors that were visible internally after dissec-
tion are also included in the analysis. n cor-
responds to the number of mice of each
genotype. Arrows in (B) indicate the onset of
tumor development for each group of mice.
An asterisk indicates p < 0.05, and a double
asterisk, p < 0.005 obtained by both the χ2
Test and the Fisher’s Exact Test.72% of the control PDK1+/flPTEN+/− mice developed tu-
mors (Table 1). These comprised a range of tumors fre-
quently observed in human disease and which exhibit
hormone or cytokine dependent growth (lymphoma
(Figure 3A), endometrial carcinoma (Figure 3C), pros-
tate carcinoma (Figure 3D), phaeochromocytoma (Fig-
ure 3F), breast adenocarcinoma (Figure 3H), or testicu-
lar tumor (Figure 3J). Other types of tumors including,
colon adenoma, thyroid carcinoma, liver hepatoma,
and lung adenocarcinoma are also observed but with
lower incidence (Table 1). In addition to these primary
tumors, pulmonary metastases were also seen.
In contrast, a markedly lower proportion of the exper-
imental PDK1−/flPTEN+/− mice had developed tumors by
15 months of age. Although 42% of control female and
20% of control male PDK1+/flPTEN+/− mice had endo-
metrial carcinoma or testicular carcinoma, no such tu-
mors are observed in any of the experimental PDK1−/fl
PTEN+/− animals (Table 1). The proportion of PDK1−/fl
PTEN+/− mice that developed lymphoma (Figure 3B),
prostate carcinoma (Figure 3E), phaeochromocytoma
(Figure 3G), and breast adenocarcinoma (Figure 3I) is
2.5- to 7.5-fold lower than observed in the control
PDK1+/flPTEN+/− animals (Table 1). One experimental
PDK1−/flPTEN+/− animal developed pancreatic carci-noma, whereas none of the control animals developed
this lesion. In total, 64 tumors were detected in 39 con-
trol PDK1+/flPTEN+/− mice, compared with only 7 tu-
mors in 23 experimental PDK1−/flPTEN+/− animals.
Employing immunohistochemistry analysis, we in-
vestigated the subcellular localization of the FOXO1
transcription factor, which is localized in the cytosol
rather than the nucleus after phosphorylation by PKB
[18], the phosphorylation of S6 protein by S6K [19], and
monitored cell proliferation by using the Ki67 cell divi-
sion marker in the mouse tumors. We first examined
prostate carcinoma (Figure 4A) and breast adenocarci-
noma (Figure 4B) from the PDK1−/flPTEN+/− and PDK1+/fl
PTEN+/− animals. In the tumors of both genotypes,
FOXO1 was predominantly in the cytosol (Figures 4A
and 4B, panels 1 and 2), indicating that PKB was acti-
vated. High levels of phospho-S6 protein were also ob-
served (Figure 4A and 4B, panels 3 and 4), suggesting
that S6K was active in the tumors of either genotype.
Comparable levels of Ki67 staining were also seen in
the prostate carcinoma and breast adenocarcinoma
from PDK1+/flPTEN+/− and PDK1−/flPTEN+/− animals in
which w25% of cells were stained (Figures 4A and 4B,
panels 5 and 6). Analogous analysis was undertaken for
the lymphoma and phaeochromocytoma and no signifi-
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1842Table 1. Incidence of Tumors in PDK1+/fl PTEN+/− and PDK1−/fl PTEN+/− Mice
PDK1+/fl PTEN+/− PDK1−/fl PTEN+/−
(n = 20 males, (n = 14 males, P Value: χ2 Test
19 females) Percentage (%) 9 females) Percentage (%) (Fisher’s Exact Test)
Tumors
Lymphoma 21 53.8 2 8.7 0.0004 (0.0003)**
Endometrial carcinoma (female) 8 42.1 0 0 0.0213 (0.0243)*
Phaeochromocytoma 15 38.4 1 4.3 0.0030 (0.0022)*
Prostate carcinoma (male) 7 35.0 1 7.1 0.0368 (0.0326)*
Breast adenocarcinoma (female) 5 26.3 1 11.1 0.3598 (0.3498)
Testicular carcinoma (male) 4 20.0 0 0 0.0748 (0.1045)
Colon adenoma 2 5.1 0 0 0.2696 (0.3918)
Lung metastasis 2 5.1 0 0 0.2696 (0.3918)
Lung adenocarcinoma 1 2.5 0 0 0.4388 (0.6290)
Thyroid carcinoma 1 2.5 0 0 0.4388 (0.6290)
Liver hepatoma 1 2.5 0 0 0.4388 (0.6290)
Pancreatic carcinoma 0 0 1 4.3 0.1892 (0.3710)
Number of mice displaying tumors 28 71.8 5 21.7 0.0001 (0.0001)**
Preneoplastic Lesions
Prostatic intraepithelial neoplasia (male) 10 50.0 3 21.4 0.0915 (0.0909)
Endometrial hyperplasia (female) 5 26.3 2 22.2 0.8153 (0.6023)
Intratubular germ cell neoplasia (male) 1 5.0 0 0 0.4129 (0.7212)
Hyperplasia seminal vesicle (male) 0 0 1 7.1 0.2250 (0.4117)
Mice without tumors displaying 4 10.2 6 26.1 0.1016 (0.1958)
preneoplastic lesions
Mice displaying no tumor-associated 7 17.9 12 52.2 0.0047 (0.0058)**
pathology
Other Nonneoplastic Lesions
Persistent trophoblast 7 36.8 1 11.1 0.1228 (0.1228)
Glomerulonephritis 2 5.1 0 0 0.2696 (0.3918)
Hydronephrosis 1 2.6 0 0 0.4388 (0.6290)
Salivary gland abscess 1 2.6 0 0 0.4388 (0.6290)
Breast abcesses (female) 0 0 1 11.1 0.1892 (0.3710)
Pancreatitis 0 0 2 8.7 0.0612 (0.1338)
n corresponds to the total number of mice and the percentages indicate the number of mice displaying the indicated pathologies. *p < 0.05;
**p < 0.005.cant differences in the staining patterns were detected
between the tumors arising in the control and experi-
mental mice (data not shown). Taken together the data
indicate that the few tumors that develop in the PDK1−/fl
PTEN+/− mice are similar to those in the control animals
and have elevated PKB and S6K activity, leading to in-
creased proliferation of cells within the tumor.
Some differences in staining between tumor types
were however observed. S6 protein was highly phos-
phorylated in all of the carcinomas but was low in the
phaeochromocytomas. In the lymphomas, which were
all of follicular origin, the S6 protein phosphorylation
was seen in centroblasts, but not in centrocytes. The
pattern of FOXO1 cytosolic staining closely matched
that seen for phospho-S6 protein. There was strong
FOXO1 cytoplasmic staining of the tumor cells of both
breast and prostate carcinoma, whereas in lymphoma
cytoplasmic staining of centroblasts was detected but
with weaker nuclear staining of some centrocytes. We
were unable to detect FOXO1 in the phaeochromocyto-
mas. Ki67 staining was observed in w10% of lympho-
mas (again mostly centroblasts) and w5% of phaeo-
chromocytomas.
Analysis of Preneoplastic Lesions
A more equal proportion of minor preneoplastic lesions
are observed in control PDK1+/flPTEN+/− and experi-
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sental PDK1−/flPTEN+/− mice. Thus w25% of each of
hese genotypes developed endometrial hyperplasia (Fig-
res 3M and 3N), whereas the proportion of PDK1−/fl
TEN+/− mice displaying prostatic intraepithelial neo-
lasia (Figures 3K and 3L) is only w2-fold lower than
hose observed in the control PDK1+/flPTEN+/− animals
Table 1). By 15 months of age, only 18% of the control
DK1+/flPTEN+/− mice were free of tumors or preneo-
lastic lesions compared to 52% of the experimental
DK1−/flPTEN+/− animals.
ersistent Trophoblast Formation in PTEN+/− Mice
nexpectedly, during the pathological analysis of
ouse tissues, we observed that 37% of the control
emale PDK1+/flPTEN+/− mice that had never been used
or breeding displayed persistent trophoblast (Table 1).
n contrast, trophoblast is not normally observed in
ice that have not previously bred. Two separate
vents must have occurred to account for this observa-
ion, namely partenogenetic fertilization of an ovum and
ormation and persistence of trophoblast. Trophoblast
evelopment from oocytes is dependent upon expres-
ion from the paternal copy of the IGF-2 gene, as the
aternal copy of IGF-2 gene is imprinted and not ex-
ressed [20]. The signaling pathway by which IGF-2
timulates trophoblast development is unknown. How-
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1843Figure 3. Histopathological Analysis of PDK1+/flPTEN+/− and PDK1−/flPTEN+/− Mice
The pathology of the several tumor types shows no differences between those occurring in PDK1+/fl PTEN+/− and those occurring in PDK1−/fl
PTEN+/−. (A and B) Non Hodgkin’s lymphomas were of a diffuse predominantly small cell type with some plasmacytoid differentiation. (D and
E) Prostatic carcinomas showed a cribriform architecture on occasion with comedo-type necrosis and invasion of the surrounding stroma. (F
and G) Phaeochromocytomas were composed of large polygonal amphophilic cells with granular cytoplasm and a rich vascular supply. (H
and I) The breast carcinomas were of an invasive ductal type eliciting a desmoplastic reaction. (J) Testicular tumors, in this example a Leydig
cell tumor, were only seen in the control animals as were endometrial carcinomas (C); preneoplastic lesions of prostate amounting to high
grade PIN (K and L) were seen in both groups of animals; as was atypical endometrial hyperplasia (M and N). Haematoxylin and eosin, original
magnification ×120. (A), (C), (D), (F), (H), (J), (K), and (M), PDK1+/fl PTEN+/−; (B), (E), (G), (I), (L), and (N), PDK1−/fl PTEN+/−.
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1844Figure 4. Immunohistochemistry Analysis of Tumors from PDK1+/flPTEN+/− and PDK1−/flPTEN+/− Mice
Sections derived from prostate carcinoma (A) and breast adenocarcinoma (B) of PDK1+/flPTEN+/− (panels I III, and V) and PDK1−/flPTEN+/−
(panels II, IV, and VI) tumors were probed with the indicated antibody, counterstained with haematoxylin, and visualized with a magnification
of ×160. In panels I and II, cytoplasmic reactivity of FOXO1 was mainly observed in tumor cells and to a lesser extent in fibroblasts of both
breast adenocarcinomas. In panels III and IV, phospho-S6 protein phosphorylated at Ser235/Ser236 was seen by strong cytoplasmic reactivity
in all tumor samples. In the breast adenocarcinoma, both tumor cells and the adjacent reactive stromal fibroblasts were observed to be
stained. In panels V and VI, Ki67 staining showed that in both types of carcinoma about 25% of the tumor cells are in cell cycle with reactivity
also noted in the stromal fibroblasts of the breast adenocarcinoma.ever, if IGF-2 stimulated trophoblast development
through the PI 3-kinase pathway, it is possible that the
enhanced PtdIns(3,4,5)P3 levels in PTEN+/− mice could
account for the presence of trophoblast. It is also pos-
sible that deregulation of the imprinting of the maternal
copy of the IGF-2 gene in the PTEN+/− oocytes could
account for the presence of trophoblast in these mice.
We also observed that a lower proportion of experi-
mental PDK1−/flPTEN+/− female mice demonstrated
persistent trophoblast compared with the control
PDK1+/flPTEN+/− mice, indicating that if trophoblast de-
velopment and survival proceeds through the PI 3-kinase
pathway, PDK1 may be involved in this process.
Potential Delay in the Onset of Tumorigenesis
in PDK1+/flPTEN+/− Mice
The strain of PTEN+/− mice employed in our study [11],
as well two other independently generated strains [9,
10], were reported to develop a significant number of
tumors by 6–8 months of age. In contrast, when we
analyzed a group of five control PDK1+/flPTEN+/− and
five experimental PDK1−/flPTEN+/− mice 8 months of
age, we were unable to detect any tumor or preneopla-
sia in these mice (data not shown), and apart from the
single control PDK1+/flPTEN+/− mouse that developed
lymphoma at 7 months of age, other tumors are only
observed after 9 months of age (Figure 2B). One expla-
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tation for this observation is the difference in genetic
ackground of our mice and those used in previous
tudies. The mice employed in our study had been
ackcrossed for at least three generations to C57BL/6J
ackground (see Experimental Procedures), whereas the
TEN+/− mice used in other studies were of a more
ixed genetic background. Another explanation is that
he littermate control mice that we deployed are
DK1+/fl rather than PDK1+/+, and our previous analysis
emonstrated that PDK1 activity in several tissues de-
ived from PDK1+/fl mice is 50%–85% of the level ob-
erved in wild-type PDK1+/+ mice [15]. It is therefore
ossible that even a modest reduction in the expres-
ion of PDK1 in the control PDK1+/flPTEN+/− mice em-
loyed in this study could have delayed the onset of
umor formation. To address this question it would be
ecessary to compare tumor development in PDK1+/fl
TEN+/− and PDK1+/+PTEN+/− mice.
DK1 as an Anticancer Target
uch effort is being devoted to developing anticancer
rugs that inhibit components of the PI 3-kinase signal-
ng pathway in order to treat tumors that have muta-
ions in PTEN and other signaling networks that elevate
he level of PtdIns(3,4,5)P3 and/or enhance PKB and
6K activity. The PDK1 hypomorphic mice utilized in
his study represent a genetic model that would be ex-
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that reduces the endogenous activity of PDK1 by 80%–
90%. The finding that a reduction in PDK1 activity by
this amount markedly protects and/or delays tumor for-
mation in PTEN+/− mice suggests that PDK1 is a prom-
ising anticancer target to prevent the formation of hu-
man tumors with elevated PKB and S6K activity.
Our results do not address the question of whether
inhibiting PDK1 in an established tumor would prevent
its growth or induce regression of the tumor. Recently
however, relatively specific, small molecule inhibitors of
PDK1 were described, which inhibited the growth and
induced apoptosis of a wide range of cancer cell lines
as well as suppressing the growth of melanoma tumors
in a nude mice model [21]. Another drug with antican-
cer properties, 7-hydroxystaurosporine (also termed
UCN-01), was originally reported to function as a CHK1
inhibitor but subsequently found to inhibit PDK1 with
similar potency [22, 23], suggesting that some of the
antitumorigenesis properties of this compound might
be mediated through inhibition of PDK1. These find-
ings, together with the genetic studies described in this
paper, suggest that PDK1 inhibitors are likely to have
utility in both the prevention and treatment of cancers
that have elevated PtdIns(3,4,5)P3 levels and/or PKB
and S6K activity.
Conclusions
Several reports suggest that some of the tumor sup-
pressor functions of PTEN are mediated independently
of its ability to breakdown PtdIns(3,4,5)P3, for exam-
ple, by dephosphorylating other substrates (reviewed
in [3, 4]) or through the ability of its C2 domain to con-
trol cell migration [24]. Moreover, elevated levels of
PtdIns(3,4,5)P3 resulting from a loss of PTEN, will acti-
vate several signaling processes in addition to PDK1-
PKB-S6K pathway [1, 2]. The importance of these other
networks in mediating the tumor suppressor activity of
PTEN is unknown, but the results described in this
study provides strong genetic evidence that PDK1 is a
key effector in mediating tumorigenesis resulting from
loss of PTEN. Our findings also support the notion
that PDK1 is an attractive target for the development
of drugs to prevent cancers that possess elevated
PtdIns(3,4,5)P3 levels and/or possess increased PKB
and S6K activity. Further work will be required to estab-
lish the mechanism by which reduction in PDK1 levels
markedly inhibits the onset of tumor formation and
whether this involves decreased activation of PKB/S6K
and/or other PDK1 targets.
Experimental Procedures
Materials
Taq DNA polymerase was purchased from Promega. Protein G-Seph-
arose and Streptavidin-Sepharose High Performance were pur-
chased from Amersham Pharmacia Biotech. Roche supplied prote-
ase inhibitor cocktail tablets.
Antibodies
The PDK1 antibody used for immunoblotting and activity was
raised in sheep against the sequence RKIQEVWRQQYQSNP
DAAVQ (residues 540–559 of mouse PDK1). The ERK2 antibody
was raised in sheep against the full-length human protein. Both
antibodies were affinity purified with the appropriate antigen. ThePTEN monoclonal antibody raised against amino acids 388–400
mapping at the C terminus of human PTEN was purchased from
Santa Cruz Biotechnology (sc-7944). Monoclonal glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was purchased from Chemi-
con (#SC5 clone). Secondary antibodies coupled to horseradish
peroxidase were from Pierce.
Mice Breeding and Genotype Analysis
All animal studies and breeding was approved by the University of
Dundee ethical committee and performed under a UK Home Office
project license. The generation and genotyping of the PTEN+/−
mice [11] and the PDK1 hypomorphic mice [15] have been de-
scribed previously. The original PTEN+/− mice employed were from
a mixed background [11] and were backcrossed for three genera-
tions with the C57BL/6J strain prior to crossing with the PDK1 hy-
pomorphic mice. The PDK1fl/fl mice and PDK1+/− mice employed in
the crosses described in Figure 1B were backcrossed for five to
seven generations to the C57BL/6J strain prior to crossing with
PTEN+/− mice. Littermates with genotypes PDK1+/flPTEN+/− (con-
trol) and PDK1−/flPTEN+/− (experimental) derived as described in
Figure 1B were maintained under standard husbandry conditions
for a period of up to 15 months of age. During this period mice
were monitored weekly for tumor development and weight loss. In
accordance with our home office license, any animal that displayed
an obvious external tumor of over 1.44 cm2, lost over 20% in body
weight, or showed signs of sickness was culled and subjected to
necropsy and pathological analysis after fixation of tissues in 10%
formalin as described below.
Analysis of Tumors
After 15 months of age, surviving mice were culled, necropsy was
performed, and all tissues were immediately fixed in 10% buffered
formalin (Pre-filled Biopsy Pots, BIOS Europe, #BP120BF) and sub-
sequently embedded in paraffin. 5 m thick sections were cut, de-
paraffinized, and stained with haematoxylin and eosin for histologi-
cal analysis employing standard protocols. Sections were viewed
on a Nikon Eclipse 600 microscope and images captured on a Ni-
kon DXM1200 digital camera supported by EclipseNet software.
Assay of PDK1 and PTEN
PDK1 was immunoblotted and assayed after its immunoprecipita-
tion from tissue extracts employing the PDKtide peptide as de-
scribed previously [15]. PTEN activity was measured following its
immunoprecipitation from tissue extracts employing 33P-labeled
PtdIns(3,4,5)P3 as described previously [25].
Immunohistochemistry Analysis
Tumor slices were generated as described above and subjected to
heat-induced antigen retrieval. Immunohistochemical staining was
performed with automated procedures at the Surgery and Molecu-
lar Oncology Department of the Ninewells hospital. The FOXO1 an-
tibody (Cell Signaling #9462) was used at a dilution of 1/160, the
Phospho-S6 Ser235/236 antibody (Cell Signaling #4857) used at a
dilution of1/400 and the Ki67 antibody employed (VectorLabs clone
SP6) at a dilution of 1/200. Antibody staining was detected using
the rabbit Vectastain ABC Kit (VectorLabs).
Statistical Analysis
The chi-square test and the Fisher’s Exact Test were performed to
compare the incidence of the different types of tumors in the two
genotypes analyzed, whereas the Student’s t test was used to
compare weights and activities measurements.
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